External broker reports(aggregated public sources), CMB International

CMB International

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

External broker reports(aggregated public sources)

Equity Bottom-Up

Jinxin Fertility Group  / Equity Bottom-Up

<ul><li>Jinxin Fertility (Jinxin) reported 1H24 revenue of RMB1,444mn, up 8.2% YoY, and non-IFRS adjusted net profit of RMB260mn, up 1.8% YoY.</li><li>Revenue/ non-IFRS adjusted net income represented 45.4%/ 47.7% of our previous full-year forecasts, both of which are in line with its pre-pandemic levels.</li><li>The number of IVF treatment cycles performed by Jinxin increased by 2.2% YoY to 15,051 in 1H24, which was negatively impacted by the delayed demand for assisted reproductive services (ARS) due to the pending launch of National Medical Insurance (NMI) coverage.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Jinxin Fertility (Jinxin) reported 1H24 revenue of RMB1,444mn, up 8.2% YoY, and non-IFRS adjusted net profit of RMB260mn, up 1.8% YoY.Revenue/ non-IFRS adjusted net income represented 45.4%/ 47.7% of our previous full-year forecasts, both of which are in line with its pre-pandemic levels.The number of IVF treatment cycles performed by Jinxin increased by 2.2% YoY to 15,051 in 1H24, which was negatively impacted by the delayed demand for assisted reproductive services (ARS) due to the pending launch of National Medical Insurance (NMI) coverage.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Jinxin Fertility (1951 HK) - Eyes on the Progress of Medical Insurance Coverage